Performance and Usability of Risk Calculators Among Ambulatory Heart Failure Patients: A Cohort Study of the Vancouver General Hospital Cardiac Function Clinic

Harleen Chohan, BSc, PharmD; Margaret Sidsworth, BSc (Pharm), ACPR; Ricky D. Turgeon, BSc (Pharm), ACPR, PharmD

Background

- Heart Failure with Reduced Ejection Fraction (HFrEF) is associated with high, but variable mortality^{1,2}.
- Several validated mortality risk calculators exist for use by clinicians, which differ in amount and types of variables needed for $use^{1,2}$.
- Risk calculators can be helpful in prognosticating HF patients and can aid in making informed treatment decisions³.
- However, it is unclear if these risk calculators provide similar estimates in predicted mortality for an individual patient.
- Large differences in predicted mortality estimates among risk calculators may worsen uncertainty or lead to conflicting decisions.

Research Objectives

- To evaluate the agreement in 1 year mortality estimates by various HF risk calculators among an ambulatory HF population at the Vancouver General Hospital (VGH) Cardiac Function Clinic.
- To evaluate feasibility of using these calculators in a busy HF Clinic.

Methods

- Study Design: Retrospective cohort study; target sample n= 210.
- Inclusion Criteria:
 - Patients with HFrEF (Left Ventricular Ejection Fraction ≤40%)
 - Initial visit to the VGH Cardiac Function Clinic (CFC) between October 2018 and December 2019.

Risk Calculators Included in Study:

- \circ 3-CHF⁴
- Barcelona (BCN) BioHF⁵
- Meta-Analysis Global Group in Chronic HF(MAGGIC)⁶
- PREDICT HF⁷
- Seattle Heart Failure Model (SHFM)⁸

Primary Outcome:

- Agreement between 1 year predicted mortality estimates by risk calculators, defined as:
- Strict, if $\leq 5\%$
- Lenient, if 6-10%
- Disagreement, if greater than 10%

Secondary Outcome:

• Ease of use, total time required to obtain collect, input and obtain predicted mortality estimates.

Analysis:

- Descriptive statistics using Microsoft Excel v. 2019.
- For missing variables, imputed cohort mean value
- Spearman's rho correlation to comparing scatterplot of predicted mortality of various calculators to MAGGIC.







Table 1' Reseline Characteristics (n=210)

Age, y	68 <u>+</u> 14.5	Comorbidities						
Male, n (%)	145 (70)	Atrial Fibrillation, n (%) 54 (26)						
NYHA, n (%)		COPD, n (%)	24 (11)					
Class I	29 (14)	Diabetes, n (%)	70 (33)					
Class II	130 (62)	Prior MI, n (%)	61 (29)					
Class III	48 (23)	Medications						
Class IV	3 (1)	ACE Inhibitors/ ARBs, n (%)	156 (74)					
Ejection Fraction (EF), %	29 <u>+</u> 7	ARNI, n (%)	8 (4)					
HF Hospitalization in prior 12 months	91 (43)	Beta Blockers, n (%)	195 (93)					
Laboratory Values		MRA, n (%)	95 (45)					
BNP (median, IQR), n=162	669 (295 -1349)	Furosemide, n (%)	144 (69)					
eGFR (median, IQR), n= 209	61 (43-83)	Statin, n (%)	150 (71)					

Table 2: Comparison of strict level of agreement among HF risk calculators, n (%)

	3-CHF	BCN-BioHF	MAGGIC	PREDICT HF
BCN-BioHF	114 (54)			
MAGGIC	77 (37)	121 (58)		
PREDICT HF	105 (50)	132 (63)	112 (53)	
SHFM	87 (41)	111 (53)	105 (50)	107 (51)

Figure 1: Predicted mortality estimates using MAGGIC as a comparator, (%)



Provincial Health Services Authority Province-wide solutions. Better health



Table 3. Risk score characteristics impacting ease of use									
	3-CHF	BCN-BioHF	MAGGIC	PREDICT HF	SHFM				
Clinical Variables	3	6	9	7	7				
Medications/Devices	2	8	2	2	5				
Medical Conditions	4	0	4	1	0				
Laboratory Values	1	6	12	1	5				
Total number of variables	10	20	27	11	17				
Average time required (mean <u>+</u> SD)	1:42 <u>+</u> 0:33	2:38 <u>+</u> 0:17	1:37 <u>+</u> 0:10	2:45 <u>+</u> 0:28	5:06 <u>+</u> 0:40				
Results									
PREDICT HF-BCN E agreement (63%).	BioHF p	air demons	strated th	ne highest s	trict				
BCN-BioHF and PRI agreement with all or	 BCN-BioHF and PREDICT-HF demonstrated at least 50% strict agreement with all other calculators. 								
MAGGIC and SHFM	demon	strated lea	st strict a	agreement	with				
3-CHF (37% and 41	%, resp	ectively).							
 Based on Figure 1, BCN-BioHF and 3-CHF calculated higher predicted mortality when compared to MAGGIC. 									
PREDICT HF most often had missing variables for Uric Acid (88%) Albumin (68%) I DL and Total Chalacterol (40%)									
	• /, == =								
Limitations									
 Missing variables im standard practice in 	other p	ublications.	values;	consistent	with				
 Race-based data not available and therefore PREDICT HF underestimated risk in Asian and black populations. 									
 Level of agreement thresholds assigned arbitrarily and may not correlate with clinical significance; definitions consistent with similar publications and limited literature to provide guidance. 									
Conclusions									
- The highest lovel of	atriat an	reement of							
Ine nignest level of a sole ulater main was a									
calculator pair was only 63%, with most pairs achieving 50%.									
 BCN-BioHF and 3-C to MAGGIC, which is 	HF calc s built in	ulated high to clinic's e	ner morta electronio	ality risk cor c medical re	npared cords.				
3-CHF not favorable due to variability in level of strict agreement.									
• PREDICT HF demonstrated at least 50% strict agreement with all									
calculators; required less variables and time, but underestimation of impact of race makes level of agreement results less reliable.									
 No clear trends observed in predicted mortality estimates for patients who died at 1 vear. 									
• Overall, no single risk calculator was most optimal for use.									
Clinicians should be aware that the choice of risk calculator used									
can significantly affect prognostic predicted mortality and have implications for treatment decisions.									
References									

- Med. 2002;347:1397-402.
- 1267. 10.1016/j.jacc.2012.12.038
- Dec;7(12):902-911. 10.4330/wjc.v7.i12.902 . Lupon J, de Antonio M, Vila J, et al. Development of a novel heart failure risk tool: the barcelona bio-heart failure risk calculator (BCN bio-HF calculator). PLoS
- One 2014;9:e85466
- failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J 2013.
- to Predict Mortality and Morbidity in Chronic Heart Failure. JAMA Cardiol. 2020;5(4):432–441

Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, et al. Long-term trends in the incidence of and survival with heart failure. N Engl. Blecker S, Paul M, Taksler G, Ogedegbe G, Katz S. Heart failure-associated hospitalizations in the United States. J Am Coll Cardiol 2013. Mar;61(12):1259-Passantino A, Monitillo F, Iacoviello M, Scrutinio D. Predicting mortality in patients with acute heart failure: Role of risk scores. World J Cardiol 2015.

Senni M, Parrella P, De Maria R, et al. Predicting heart failure outcome from cardiac and comorbid conditions: the 3C-HF score. Int J Cardiol 2013;163:206-11

E Pocock SJ, Ariti CA, McMurray JJ, Maggioni A, Køber L, Squire IB, et al. Meta-Analysis Global Group in Chronic Heart Failure Predicting survival in heart Simpson J, Jhund PS, Lund LH, et al. Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry

Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006;113:1424-33.